[go: up one dir, main page]

FI946104L - Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi - Google Patents

Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi Download PDF

Info

Publication number
FI946104L
FI946104L FI946104A FI946104A FI946104L FI 946104 L FI946104 L FI 946104L FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A FI 946104 L FI946104 L FI 946104L
Authority
FI
Finland
Prior art keywords
preparation
highly concentrated
concentrated immunoglobulin
immunoglobulin preparation
highly
Prior art date
Application number
FI946104A
Other languages
English (en)
Swedish (sv)
Other versions
FI111224B (fi
FI946104A0 (fi
Inventor
Johann Eibl
Yendra Linnau
Wolfgang Teschner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI946104(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI946104A0 publication Critical patent/FI946104A0/fi
Publication of FI946104L publication Critical patent/FI946104L/fi
Application granted granted Critical
Publication of FI111224B publication Critical patent/FI111224B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI946104A 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi FI111224B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
DE4344824 1993-12-28

Publications (3)

Publication Number Publication Date
FI946104A0 FI946104A0 (fi) 1994-12-27
FI946104L true FI946104L (fi) 1995-06-29
FI111224B FI111224B (fi) 2003-06-30

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946104A FI111224B (fi) 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi

Country Status (15)

Country Link
US (1) US5608038A (fi)
EP (1) EP0661060B1 (fi)
JP (1) JP3040678B2 (fi)
AT (2) AT407707B (fi)
CA (1) CA2138853A1 (fi)
CZ (1) CZ284186B6 (fi)
DE (2) DE4344824C1 (fi)
DK (1) DK0661060T3 (fi)
ES (1) ES2158877T3 (fi)
FI (1) FI111224B (fi)
HR (1) HRP941018B1 (fi)
HU (1) HU220766B1 (fi)
NO (1) NO315260B1 (fi)
RU (1) RU2104713C1 (fi)
YU (1) YU77994A (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP2275119B1 (en) * 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE69810481T2 (de) * 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2006012500A2 (en) * 2004-07-23 2006-02-02 Genentech, Inc. Crystallization of antibodies or fragments thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN101679507A (zh) 2007-03-29 2010-03-24 艾博特公司 结晶抗人类il-12抗体
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
TWI532498B (zh) * 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
TW201039854A (en) * 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
WO2015071348A1 (en) 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
KR102413592B1 (ko) 2016-10-21 2022-06-27 암젠 인크 약학적 제형 및 그의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763B1 (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
EP0168506B2 (en) * 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
ATA237894A (de) 2000-10-15
US5608038A (en) 1997-03-04
DK0661060T3 (da) 2001-07-30
AT407707B (de) 2001-05-25
JP3040678B2 (ja) 2000-05-15
ATE201328T1 (de) 2001-06-15
HRP941018B1 (en) 1999-12-31
FI111224B (fi) 2003-06-30
EP0661060A3 (de) 1997-01-15
CZ284186B6 (cs) 1998-09-16
HU220766B1 (hu) 2002-05-28
YU77994A (sh) 1997-03-07
ES2158877T3 (es) 2001-09-16
DE59409761D1 (de) 2001-06-28
EP0661060A2 (de) 1995-07-05
RU2104713C1 (ru) 1998-02-20
FI946104A0 (fi) 1994-12-27
EP0661060B1 (de) 2001-05-23
JPH07206709A (ja) 1995-08-08
NO945045L (no) 1995-06-29
HU9403795D0 (en) 1995-02-28
CA2138853A1 (en) 1995-06-29
NO945045D0 (no) 1994-12-27
CZ328494A3 (en) 1995-07-12
HRP941018A2 (en) 1997-04-30
HUT70449A (en) 1995-10-30
NO315260B1 (no) 2003-08-11
DE4344824C1 (de) 1995-08-31

Similar Documents

Publication Publication Date Title
FI946104L (fi) Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi
FI960948L (fi) Pakkaus ja menetelmä mainitun pakkauksen tuottamiseksi
FI942745L (fi) Fluoreeniyhdisteitä ja valmistusmenetelmä
FI953904L (fi) Varmuusdokumentti ja menetelmä sen valmistamiseksi
FI941137L (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI956135A0 (fi) Erotusmenetelmä
FI945507L (fi) Monikäyttömenetelmä
FI962377L (fi) Humanisoituja vasta-aineita ja niiden käyttö
FI935665L (fi) Maitotuote ja menetelmä sen valmistamiseksi
FI940585L (fi) Pinnoittamattomat tabletit ja menetelmä niiden valmistamiseksi
FI954246L (fi) Uusia A83543-yhdisteitä ja menetelmä niiden valmistamiseksi
FI944961L (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
FI935465L (fi) Termoplastinen koostumus, menetelmä sen valmistamiseksi ja sen käyttö
DE69414001D1 (de) Bestimmungsmethode
FI943383L (fi) Yhdiste FO-1289 ja menetelmä sen valmistamiseksi
FI943207L (fi) 4,5-dihydrogeldanamysiinin ja sen hydrokinonin valmistusmenetelmä ja käyttö
FI930326L (fi) Pinnoiteseos ja menetelmä sen valmistamiseksi
FI961937L (fi) Juoma ja menetelmä sen valmistamiseksi
FI942703L (fi) Sinkkiantimonaattianhydridi ja menetelmä sen valmistamiseksi
FI962486L (fi) Pakkaus ja menetelmä sekä laite sen valmistamiseksi
FI925357L (fi) Rakennusmenetelmä
FI954499L (fi) Menetelmä ja analyysi
FI961093L (fi) Poregranulaatti ja menetelmä sen valmistamiseksi
FI955708L (fi) Menetelmä 2-fenyyli-3-aminopiperidiinin valmistamiseksi ja erottamiseksi
FI931232L (fi) Makeutusaine, menetelmä sen valmistamiseksi ja sen käyttö

Legal Events

Date Code Title Description
MA Patent expired